US7166310B2 - Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament - Google Patents

Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament Download PDF

Info

Publication number
US7166310B2
US7166310B2 US10/451,714 US45171404A US7166310B2 US 7166310 B2 US7166310 B2 US 7166310B2 US 45171404 A US45171404 A US 45171404A US 7166310 B2 US7166310 B2 US 7166310B2
Authority
US
United States
Prior art keywords
extract
weight
group
mixtures
stabiliser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/451,714
Other versions
US20040137088A1 (en
Inventor
Egon Koch
Clemens Erdelmeier
Joachim Herrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Willmar Schwabe GmbH and Co KG
Original Assignee
Dr Willmar Schwabe GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Willmar Schwabe GmbH and Co KG filed Critical Dr Willmar Schwabe GmbH and Co KG
Assigned to WILLMAR SCHWABE GMBH & CO. reassignment WILLMAR SCHWABE GMBH & CO. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HERRMANN, JOACHIM, KOCH, EGON, ERDELMEIER, CLEMENS
Publication of US20040137088A1 publication Critical patent/US20040137088A1/en
Application granted granted Critical
Publication of US7166310B2 publication Critical patent/US7166310B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives

Definitions

  • the present invention relates to an improved and stable (i.e. colour-stable and, optionally, stable with regard to its hyperforin content) extract from the exposed parts of Hypericum perforatum L ., to a method for the preparation thereof, and to pharmaceutical preparations and topical medicaments containing this extract, in particular, gels for treating skin and mucous membrane irritations and disorders such as acne, atopic dermatitis, neuro-dermatitis, psoriasis, stomatitis, herpes zoster, herpes labialis, warts, varicella (chicken-pox), sores, burns and other bacterial and viral skin and mucous membrane infections and skin disorders that are accompanied by cell proliferation and inflammation.
  • an improved and stable extract i.e. colour-stable and, optionally, stable with regard to its hyperforin content
  • Hypericum extract has been used for the treatment of nervous disorders for many years past. Its application for depression and psycho-autonomic disorders has greatly increased over the past few years in the light of the favourable results of clinical trials [W. E. Müller, A. Singer, M. Wonnemann, DAZ 139 (17), 49–58 (1999)].
  • EP-A-O 599 307 describes a primary extract of St. John's wort. This primary extract was obtained by simple extraction of the drug with 96% or 60% aqueous ethanol.
  • DE-A-196 19 512 also DE-A-197 14 450, extracts are described that show a stable content of the otherwise highly unstable St. John's wort component hyperforin.
  • WO 99/40905 describes the use of St. John's wort extract for the treatment and prophylaxis of dementia.
  • DE-A-199 03 570 hyperforin preparations are described, in which hyperforin is present in the form of an extract of St. John's wort.
  • hypericum extracts particularly in the form of St. John's wort oil, for the treatment of sores, ulcers, burns, myalgia, bruises, etc [P. Maisenbacher, Tübingen University thesis, 1991].
  • These empirical medical applications would appear to have a sound foundation in theoretical thinking and experimental investigations.
  • hypericum extracts and individual ingredients make good use of anti-viral, anti-bacterial, anti-proliferative and inflammation-inhibiting properties.
  • Hypericin and pseudo-hypericin have been identified as the definitive ingredients with an anti-viral action in hypericum extracts [EP 0 256 452] [Lavie, G; Mazur, Y; Lavie, D; Meruelo, D: Med. Res. Rev. 15, (2), 111–119 (1995) [LAVIE, D; VALENTINE, F; LEVIN, B; MAZUR, Y; GALLO, G; LAVIE, D; WEINER, D; MERUELO, D. Proc. Natl. Acad. Sci. USA 86, (15) 5963–5967 (1989)].
  • Hyperforin is particularly effective against gram-positive bacteria, and possesses antibacterial properties even, for example, in methicillin-resistant staphylococci, which represent major irritants in skin infections [Schempp, Ch. M; Pelz, K; Wittmer, A; Schoepf, E; Simon, J. C. Lancet 353 (9170), 2129—2129 (1999)]. This seems to be significant, since there is for example a close correlation between streptococci and staphylococci infections on the one hand and the induction, or recurrence, of psoriasis on the other.
  • hypericin also has anti-proliferative properties and is therefore currently being clinically tested in tumours, in combination with photo-dynamic therapy. Suppression of cell proliferation is in all probability responsible for the inhibition of various protein kinases which play a part in intra-cellular signal transduction. Since this effect is also contingent on light, again the therapeutic use of this effect for topical application suggests itself.
  • hyperforin possesses striking anti-phlogistic properties, whereby it suppresses for example the invasion of neutrophile granulocytes into inflamed tissue.
  • the flavonoids contained in the hypericum extracts according to the invention also have inflammation-inhibiting effects.
  • flavonoids have anti-oxidative properties, and are thus well placed to suppress the tissue-damaging effects of reactive oxygen radicals that are formed from leucocytes. It is known, moreover, that flavonoids can affect an array of enzyme systems that drive important cellular reactions which play a part in the pathogenesis of psoriasis, such as cell-proliferation and immune responses.
  • Psoriasis is a chronic skin ailment, hallmarked by hyper-proliferation and abnormal differentiation of keratinocytes, together with inflammation of the epidermis and dermis. While temporary alleviation of the symptoms and long-term containment of the condition is certainly possible using standard methods of treatment, a permanent cure of the condition is rarely achieved. All types of therapy hitherto in use have drawbacks that are serious to a greater or lesser degree (unpleasant smell, skin irritation, increased risk of skin cancer, teratogenicity, etc). Furthermore, there is an urgent need for effective methods for the treatment of psoriasis that produce few or no side-effects. Under our invention, this need is satisfied by the use of extracts of the overground parts of St. John's wort ( Hypericum perforatum L .), which contain useful concentrations of hypericin, hyperforin and flavonoids.
  • acne is an inflammation of the sebaceous glands, which starts with the decay of sebaceous-gland follicles. Androgenous hormones are thought to trigger acne by stimulating the production of secretions in the sebaceous glands. If run-off disturbances arise simultaneously, this may lead to bacterial population of sebum, with subsequent peri-follicular inflammation, abscess formation, colliquation of the tissue and a foreign-body reaction. There are indications that the male hormone testosterone is converted into the biologically more potent form dihydro-testosterone in the skin of people suffering from acne when intensified under the effect of the enzyme 5 ⁇ reductase.
  • hyperforin hypericin as dermatics, as well as extracts that contain those components, is already known from DE 198 54 446 A1 and WO 00/30660.
  • the drawbacks just described can, according to the invention, be eliminated by using the colour-stable extract here described.
  • the extraction of polyphenolic tannins can be suppressed.
  • the green pigments present in the resulting primary extract can be largely removed by filtration via an adsorbing agent, for example an adsorbing resin.
  • the extract finally obtained according to the invention is visually and cosmetically acceptable and can readily be incorporated into ointments, creams, gels, etc, for external use.
  • the extract according to the invention is thus stable in the sense of being colour-stable; in other words, there is no unwanted change of color over the period when the medicament is being stored and used.
  • HPLC conditions for determining chlorophylls and proanthocyanidines are as follows:
  • Period Eluant A Eluant B Flow, ml/min 0.0 100 0 1.2 5.0 99 1 1.2 55.0 60 40 1.2 90.0 1 99 1.2 100.0 1 99 1.2 105.0 100 0 1.2
  • chlorophylls appear at a detection wavelength of 400 nm with a retention-time in the 80 to 100 mins range.
  • Proanthocyanidines appear at a detection wavelength of 220 nm, as a broad peak with a retention-time in the range of 20 to 60 mins.
  • the corresponding peaks for chlorophylls and proanthocyanidines appear at a 60% aqueous ethanol control extract, and are greatly reduced or are absent altogether in the extracts according to the invention.
  • Extraction agents deployed according to the invention are acetone, ethanol or a solvent mixture of acetone and ethanol.
  • Preferred extraction agents are aqueous acetone, particularly ⁇ 90% aqueous acetone, aqueous ethanol, especially ⁇ 90% aqueous ethanol, or a mixture of both solvents, where a mixture of aqueous acetone and aqueous ethanol in the ratio of 8:2 is preferred, or a mixture of 95% by weight acetone and 92% by weight ethanol in the ratio of 8:2, is particularly preferred.
  • An adsorbing agent such as adsorbing resin can be deployed using the method according to the invention.
  • adsorbing resin examples are resins based on polystyrol, such as the Diaion HP resins made by Mitsubishi Kasei Corporation.
  • Another example of a suitable adsorbing agent is argillaceous earth, for example the Tonsil type, made by Südchemie plc.
  • the extracts of Hypericum perforatum L. according to the invention, with a reduced chlorophyll content and reduced proanthocyanidines content, should preferably have a hyperforin content of at least 2%, a total hypericin content of at least 0.2% and a total flavone content of at least 2%.
  • a hyperforin content of at least 4%, a total hypericin content of at least 0.4% and a total flavone content of at least 4% especially a hyperforin content of 4–8%, a total hypericin content of 0.4–1.0% and a total flavone content of 4–8%.
  • excipients in normal pharmaceutical use for topical application are polyacrylic acid, methyl cellulose and other cellulose derivatives.
  • the extract according to the invention has the advantage of containing the pharmacologically-relevant ingredients hyperforin, hypericins and flavones in ideal proportions. Given the complex pathogenesis of psoriasis, it would not be expected that substances with a single, selective mode of working could be successfully applied in the treatment of this ailment. This view is supported by clinical experience with established methods of therapy.
  • the Hypericum extract according to the invention is thus exceptional in combining various modes of working that are vital in the treatment of psoriasis and other skin ailments (e.g. anti-viral, antibacterial, anti-phlogistic, anti-proliferative), such that it clearly surpasses the combined effect of the individual components on the working of individual substances (synergistic effect).
  • stabilisers can be added to the extract and/or the pharmaceutical preparation (e.g. gel) in an amount sufficient to stabilise hyperforin.
  • the stabilisers themselves, we are talking about the stabilisers described in DE-A-196 19 512, which are preferably present at concentrations of 0.01% to 5%, especially 0.2% to 1%, in relation to the extract.
  • the stabilisers it may be a case of using the complexing agents described in DE-A-199 03 570 in sufficient amounts to complex the hyperforin. Explicit reference is made to both these references in connection with stabilising hyperforin.
  • the extract showed no change of color at room temperature or at 30° C. over a period of 6 months.
  • Component Quantity portion (%) St. John's wort extract according to the 2.5 invention, in accordance with Example 1 Polyacrylic acid 1.5 Propylene glycol 2.5 Tromethamine solution (40%, in water) 5.5 Ethanol 96% by weight 40.0 Purified water 48.0
  • the gel former (polyacrylic acid 1–3%, preferably 1.5%) was dispersed in a mixture of water, ethanol and propylene glycol.
  • the extract (0.5–5%, preferably 2.5%) was added and blended in.
  • the tromethamine solution was added and blended in small increments. A homogenous gel is formed. Stabilisers such as ascorbic acid can then be added to this basic recipe.
  • the preparation showed no change of color at room temperature or at 30° C. over a 6-month period.
  • St. John's wort extract The St. John's wort extract, tenside (macrogol-glycerol-hydroxy-stearate), isopropyl-myristate, neutral oil and propylene glycol were blended until homogenous. Next, water was added while stirring. A homogenous gel is formed. Stabilisers such as ascorbic acid can be added to this basic recipe.
  • the preparation showed no change of color at room temperature or at 30° C. over a 6-month period.
  • the vaseline was melted by heating; propylene glycol was added and blended in.
  • the St. John's wort extract was then added, blended in and stirred while cold. A homogenous gel is formed.
  • the preparation showed no change of color at room temperature or at 30° C. over a 6-month period.
  • HSV-1 Herpes simplex 1 strain of virus
  • source: McIntyre, ATCC was used to test the anti-viral properties of the extract in this invention.
  • test substances were blended with 980 ⁇ l of virus solution at a quantity of 20 ⁇ l to assess the cyto-toxic concentration (TC 50 ) and placed on a micro-titre dish with 3-day-old ape kidney cells (verocells) following a one-hour incubation period. After incubation of the dishes at 37° C. in an incubator for 5 days, a visual readout of the cell culture was performed, following HSV-1-specific cyto-pathogenic changes (CPE).
  • CPE HSV-1-specific cyto-pathogenic changes
  • the extract according to the invention or hypericin was added to a closed cohort of verocells in micro-titre dishes at various concentrations. After incubating for one hour, HSV-1 was then added at a concentration of 3000 TCID 50 /ml. The dishes were then incubated at 37° C. and 5% CO 2 in the incubator. Assessment was carried out after 48–72 hours, using monoclonal antibodies and a specific colouring method.
  • TC 50 cyto-toxic concentration
  • IC 50 virus-inhibiting concentration
  • virus quantities applied were 1.5 ⁇ 10 7 TCID 50 .
  • “Virus deactivation” was calculated from the difference between the initial virus quantities and the virus titres given above. N.d. means “not determined”, due to cyto-toxicity or the “virus-deactivating” effect found in preliminary trials.
  • hypericin showed a clear virus-deactivating action, as expected. It amounted to approx. 4 log10 stages at 100 ⁇ g/ml. Surprisingly, however, the extract according to the invention produced a significantly more potent effect in that it showed an equally strong inhibiting effect even at a concentration of just 10 ⁇ g/ml, comparable to the more intrinsically anti-viral St. John's wort extract ingredient hypericin, which is contained in the extract according to the invention at a portion of 0.5% only.
  • the potent anti-viral effect of the extract according to the invention was confirmed in the inhibition test.
  • the extract according to the invention showed significantly more potent antibacterial effects on the gram-positive bacteria tested than would have been expected on the basis of its content of hyperforin, which is thought to be an ingredient with intrinsically antibacterial effects.
  • hypericum extract according to the invention also those of isolated ingredients, were tested in the Oleum Crotonis-ear-oedema model on male NRMI mice.
  • the test substances were applied to the right ear in 10 ⁇ l acetone, whereas the left ear was treated with 10 ⁇ l acetone alone, as a control. 30 mins later, a local inflammation was triggered at the left ear by applying 50 ⁇ g Oleum Crotonis in 10 ⁇ l acetone.
  • MPO myelo-peroxidase
  • HTAB hexadecyl-trimethyl ammonium bromide
  • Determining the MPO was performed in micro-titre dishes after adding H 2 O 2 and the O-dianisidine-dihydrochloride indicator as a kinetic measure, over a period of 5 mins at 450 nm. Assessment was carried out against a standard curve with horseradish peroxidase, and was obtained as an mU enzyme activity per mg of tissue.
  • the extract according to the invention was applied in the investigation described above in quantities of 1000 ⁇ g.
  • the extract according to the invention used in accordance with Example 1 contains 6.3% hyperforin as the active ingredient, with quantitatively the largest portion in the extract.
  • 1000 ⁇ g extract thus corresponds to 63 ⁇ g hyperforin.
  • the comparison substances were again administered in quantities of 250 ⁇ g. This means the test substances were administered at about four times the amount compared with hyperforin.
  • the extract according to the invention shows markedly greater inhibition compared with hyperforin, used as a test substance.
  • the synergistic effect between hyperforin and other ingredients of the extract according to the invention that are relevant for its effectiveness.
  • flavonoids e.g. amentoflavone, biapigenine, camphor oil, luteolin, quercetin
  • the effects of the extracts according to the invention and various ingredients on the proliferation of human keratinocytes were obtained by using the HaCaT cell-line.
  • the cells (10,000–15,000) were disseminated in 200 ⁇ l DMEM with 5% foetal calf serum in 96-well F-form micro-titre dishes and incubated at 37° C. at absence of test substances in an incubator.
  • Cell proliferation was determined by measuring the incorporation of 3 H methyl-thymidine (0.5 ⁇ Ci/well) over the last 6 hours in the culture.
  • the anti-proliferative properties of the extract according to the invention quite plainly have 5 their basis in the combined effect of hypericin and hyperforin, together with certain flavone compounds, for example isoquercitrin and luteolin.
  • the organic phase was removed and transferred over to a small glass tube. Extraction was then repeated by again applying 2.5 ml ethyl acetate.
  • the combined organic phases were evaporated down at 37° C. under N 2 fumigation until dry; the residue was taken into 50 ⁇ l ethyl acetate and then separated out twice on a silica-gel 60 TLC dish, with ethyl acetate/cyclohexane (1:1) as mobile phase.
  • the testosterone metabolites so formed were localised with the aid of a linear analyser, and inhibition of 5 ⁇ reductase was obtained at the dihydro-testosterone peak by comparison with the solvent control.
  • the extract according to the invention shows a marked inhibiting effect on 5a reductase.
  • concentration of test substances used at 30 ⁇ g/ml, corresponds to the concentration of hyperforin, which is quantitatively the most important ingredient in the extract according to the invention in accordance with Example 1, fraction 1.
  • Hyperforin which is known to be chemically unstable, is included complete in a gel according to the invention in accordance with Example 2a, as can be shown by the quantitative determination of the hyperforin it contains; in other words, no decomposition occurs in producing the gel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to an improved and stable (i.e. color-stable and, optionally, stable with regard to its hyperforin content) extract from the overground parts of Hypericum perforatum L., to a method for the preparation thereof, and to pharmaceutical preparations and topical medicaments that contain this extract; in particular, gels for treating skin and mucous membrane irritations and disorders such as acne, atopic dermatitis, neuro-dermatitis, psoriasis, stomatitis, herpes zoster, herpes labialis (lip herpes), warts, varicella (chicken-pox), sores, burns and other bacterial and viral skin and mucous membrane infections and skin disorders that are accompanied by cell proliferation and inflammation.

Description

This application is a National Stage of International Application No. PCT/EP01/15281, filed Dec. 21, 2001.
The present invention relates to an improved and stable (i.e. colour-stable and, optionally, stable with regard to its hyperforin content) extract from the exposed parts of Hypericum perforatum L., to a method for the preparation thereof, and to pharmaceutical preparations and topical medicaments containing this extract, in particular, gels for treating skin and mucous membrane irritations and disorders such as acne, atopic dermatitis, neuro-dermatitis, psoriasis, stomatitis, herpes zoster, herpes labialis, warts, varicella (chicken-pox), sores, burns and other bacterial and viral skin and mucous membrane infections and skin disorders that are accompanied by cell proliferation and inflammation.
Hypericum extract has been used for the treatment of nervous disorders for many years past. Its application for depression and psycho-autonomic disorders has greatly increased over the past few years in the light of the favourable results of clinical trials [W. E. Müller, A. Singer, M. Wonnemann, DAZ 139 (17), 49–58 (1999)]. EP-A-O 599 307 describes a primary extract of St. John's wort. This primary extract was obtained by simple extraction of the drug with 96% or 60% aqueous ethanol. In DE-A-196 19 512, also DE-A-197 14 450, extracts are described that show a stable content of the otherwise highly unstable St. John's wort component hyperforin. WO 99/40905 describes the use of St. John's wort extract for the treatment and prophylaxis of dementia. Lastly, in DE-A-199 03 570, hyperforin preparations are described, in which hyperforin is present in the form of an extract of St. John's wort.
There is a venerable tradition of local application of hypericum extracts, particularly in the form of St. John's wort oil, for the treatment of sores, ulcers, burns, myalgia, bruises, etc [P. Maisenbacher, Tübingen University dissertation, 1991]. These empirical medical applications would appear to have a sound foundation in theoretical thinking and experimental investigations. There are many indications that hypericum extracts and individual ingredients make good use of anti-viral, anti-bacterial, anti-proliferative and inflammation-inhibiting properties.
Hypericin and pseudo-hypericin have been identified as the definitive ingredients with an anti-viral action in hypericum extracts [EP 0 256 452] [Lavie, G; Mazur, Y; Lavie, D; Meruelo, D: Med. Res. Rev. 15, (2), 111–119 (1995) [LAVIE, D; VALENTINE, F; LEVIN, B; MAZUR, Y; GALLO, G; LAVIE, D; WEINER, D; MERUELO, D. Proc. Natl. Acad. Sci. USA 86, (15) 5963–5967 (1989)]. These napthodianthrones also possess anti-viral properties against viruses (except retro-viruses) that are equipped with a lipid coating, for example the herpes virus. The anti-viral potency of hypericin is entirely contingent on photo-dynamic action, and is greatly intensified by the effect of visible light, a property that meant this ingredient was destined for local application on virus infections of the skin. Anti-viral effects have also been demonstrated for acetone and water extracts of hypericum, which contained predominantly catechols and flavone-aglyca [Erdelmeier, C; Koch, E; Hörr, R. Hypericum perforatum L.—St. John's wort, Chemical, Pharmacological and Clinical Aspects, in “Studies in Natural Product Chemistry” vol. 22, Atta-Ur-Rahman (editor), Elsevier Amsterdam, 2000). A therapeutically-relevant anti-viral effect might also be expected, especially when applied topically, in this ingredient. And in fact it has now been shown that extracts produced by this invention do indeed have anti-viral effects that are significantly greater than is the case with pure hypericin (see Example 3). At the same time, such extracts have a high therapeutic index, which hallmarks the difference between the desired anti-viral properties and non-specific cytotoxic effects.
Antibacterial effects of hypericum extracts are very well documented and can be attributed primarily to the hyperforin content. Hyperforin is particularly effective against gram-positive bacteria, and possesses antibacterial properties even, for example, in methicillin-resistant staphylococci, which represent major irritants in skin infections [Schempp, Ch. M; Pelz, K; Wittmer, A; Schoepf, E; Simon, J. C. Lancet 353 (9170), 2129—2129 (1999)]. This seems to be significant, since there is for example a close correlation between streptococci and staphylococci infections on the one hand and the induction, or recurrence, of psoriasis on the other. What we found surprisingly are the antibacterial effects of an extract according to the invention, which are significantly stronger than might have been expected on the basis of its hyperforin content. This means either that the extracts according to the invention contain other effective antibacterial ingredients, or that the effect of hyperforin is intensified by those components of the extract.
Besides its anti-viral effects, hypericin also has anti-proliferative properties and is therefore currently being clinically tested in tumours, in combination with photo-dynamic therapy. Suppression of cell proliferation is in all probability responsible for the inhibition of various protein kinases which play a part in intra-cellular signal transduction. Since this effect is also contingent on light, again the therapeutic use of this effect for topical application suggests itself. Here, we should be thinking primarily of the treatment of psoriasis, which is characterised by the hyper-proliferation of epidermal cells.
In addition, hyperforin possesses striking anti-phlogistic properties, whereby it suppresses for example the invasion of neutrophile granulocytes into inflamed tissue. The flavonoids contained in the hypericum extracts according to the invention also have inflammation-inhibiting effects. In particular, flavonoids have anti-oxidative properties, and are thus well placed to suppress the tissue-damaging effects of reactive oxygen radicals that are formed from leucocytes. It is known, moreover, that flavonoids can affect an array of enzyme systems that drive important cellular reactions which play a part in the pathogenesis of psoriasis, such as cell-proliferation and immune responses.
Psoriasis is a chronic skin ailment, hallmarked by hyper-proliferation and abnormal differentiation of keratinocytes, together with inflammation of the epidermis and dermis. While temporary alleviation of the symptoms and long-term containment of the condition is certainly possible using standard methods of treatment, a permanent cure of the condition is rarely achieved. All types of therapy hitherto in use have drawbacks that are serious to a greater or lesser degree (unpleasant smell, skin irritation, increased risk of skin cancer, teratogenicity, etc). Furthermore, there is an urgent need for effective methods for the treatment of psoriasis that produce few or no side-effects. Under our invention, this need is satisfied by the use of extracts of the overground parts of St. John's wort (Hypericum perforatum L.), which contain useful concentrations of hypericin, hyperforin and flavonoids.
One of the most prevalent skin ailments is acne. This is an inflammation of the sebaceous glands, which starts with the decay of sebaceous-gland follicles. Androgenous hormones are thought to trigger acne by stimulating the production of secretions in the sebaceous glands. If run-off disturbances arise simultaneously, this may lead to bacterial population of sebum, with subsequent peri-follicular inflammation, abscess formation, colliquation of the tissue and a foreign-body reaction. There are indications that the male hormone testosterone is converted into the biologically more potent form dihydro-testosterone in the skin of people suffering from acne when intensified under the effect of the enzyme 5α reductase. Inhibition of 5α reductase therefore presents a possibility for the treatment of acne. It was surprising to us that extracts according to the invention and various ingredients contained therein exert a marked inhibiting effect on this enzyme, and thus are therefore exceptionally well suited for the treatment of acne, given their antibacterial and inflammation-inhibiting properties.
The use of hyperforin, hypericin as dermatics, as well as extracts that contain those components, is already known from DE 198 54 446 A1 and WO 00/30660.
These total extracts are produced with a solvent mixture comprising ethanol with a high water content. According to the experience, these extracts contain high quantities of polyphenolic tannins (proanthocyanidines), which turn increasingly brown over time and ultimately make the preparation cosmetically unacceptable. This applies equally to the green pigments (chlorophylls) which pass from plant material in practically all ethanol-water-extracts. These pigments severely colour the extract and make them objectionable in appearance. Such extracts have been found completely unacceptable by patients. This applies in particular in the case of application to uncovered body areas.
The drawbacks just described can, according to the invention, be eliminated by using the colour-stable extract here described. Surprisingly, by an appropriate selection of extraction agent, the extraction of polyphenolic tannins can be suppressed. The green pigments present in the resulting primary extract can be largely removed by filtration via an adsorbing agent, for example an adsorbing resin. The extract finally obtained according to the invention is visually and cosmetically acceptable and can readily be incorporated into ointments, creams, gels, etc, for external use. The extract according to the invention is thus stable in the sense of being colour-stable; in other words, there is no unwanted change of color over the period when the medicament is being stored and used.
The absence, or at least substantial reduction, of any green pigments (chlorophylls) content and of polyphenolic tannins (proanthocyanidines) content can be demonstrated by the fact that absorption bands in the VIS spectrum of this extract, typical of chlorophyll, are greatly reduced between 600 and 700 nm or are absent altogether, and that no signal, or only a greatly-reduced signal, indicating the presence of proantho-cyanidines and chlorophyll, is visible in HPLC analysis.
The HPLC conditions for determining chlorophylls and proanthocyanidines are as follows:
  • Column: Spherisorb 100 RP-18/Merck (column length/diameter: 250/4 mm)
  • Eluant: A: H2O 100 parts/H3PO4 0.3 parts/Triethylamine 0.2 parts
    • B: Acetonitril (ACN) 100 parts/H3PO4 0.3 parts/Triethlyamine 0.2 parts
Period Eluant A Eluant B Flow, ml/min
0.0 100 0 1.2
5.0 99 1 1.2
55.0 60 40 1.2
90.0 1 99 1.2
100.0 1 99 1.2
105.0 100 0 1.2
  • Flow: 1.2 ml/min
  • Analysis time: 100 min/gradient
  • Detection: UV 200–600 nm
  • Test quantity: 20 μl, approx 5 mg/ml
  • Column oven: 25° C.
Under the above HPLC conditions, chlorophylls appear at a detection wavelength of 400 nm with a retention-time in the 80 to 100 mins range.
Proanthocyanidines appear at a detection wavelength of 220 nm, as a broad peak with a retention-time in the range of 20 to 60 mins. The corresponding peaks for chlorophylls and proanthocyanidines appear at a 60% aqueous ethanol control extract, and are greatly reduced or are absent altogether in the extracts according to the invention.
Extraction agents deployed according to the invention are acetone, ethanol or a solvent mixture of acetone and ethanol. Preferred extraction agents are aqueous acetone, particularly ≧90% aqueous acetone, aqueous ethanol, especially ≧90% aqueous ethanol, or a mixture of both solvents, where a mixture of aqueous acetone and aqueous ethanol in the ratio of 8:2 is preferred, or a mixture of 95% by weight acetone and 92% by weight ethanol in the ratio of 8:2, is particularly preferred.
An adsorbing agent such as adsorbing resin can be deployed using the method according to the invention. Examples are resins based on polystyrol, such as the Diaion HP resins made by Mitsubishi Kasei Corporation. Another example of a suitable adsorbing agent is argillaceous earth, for example the Tonsil type, made by Südchemie plc.
The extracts of Hypericum perforatum L. according to the invention, with a reduced chlorophyll content and reduced proanthocyanidines content, should preferably have a hyperforin content of at least 2%, a total hypericin content of at least 0.2% and a total flavone content of at least 2%. Particularly preferred is a hyperforin content of at least 4%, a total hypericin content of at least 0.4% and a total flavone content of at least 4%, especially a hyperforin content of 4–8%, a total hypericin content of 0.4–1.0% and a total flavone content of 4–8%.
In the St. John's wort extract preparations according to the invention, we are concerned in particular with hydrophile or lipophile homogenous, single-phase preparations in gel form, for topical application (see examples 2a–2c). The gels are to be applied gently to the skin and rubbed in. In particular, they are cosmetically acceptable; in other words, there will be no unusual change of color of the skin when applied to uncovered parts of the body.
Examples of suitable excipients in normal pharmaceutical use for topical application, and suitable gel foundations in normal use, are polyacrylic acid, methyl cellulose and other cellulose derivatives.
Furthermore, the extract according to the invention has the advantage of containing the pharmacologically-relevant ingredients hyperforin, hypericins and flavones in ideal proportions. Given the complex pathogenesis of psoriasis, it would not be expected that substances with a single, selective mode of working could be successfully applied in the treatment of this ailment. This view is supported by clinical experience with established methods of therapy. The Hypericum extract according to the invention is thus exceptional in combining various modes of working that are vital in the treatment of psoriasis and other skin ailments (e.g. anti-viral, antibacterial, anti-phlogistic, anti-proliferative), such that it clearly surpasses the combined effect of the individual components on the working of individual substances (synergistic effect).
In order to stabilise the hyperforin in the extract or the pharmaceutical preparation, stabilisers can be added to the extract and/or the pharmaceutical preparation (e.g. gel) in an amount sufficient to stabilise hyperforin. As for the stabilisers themselves, we are talking about the stabilisers described in DE-A-196 19 512, which are preferably present at concentrations of 0.01% to 5%, especially 0.2% to 1%, in relation to the extract. In addition, with regard to the stabilisers, it may be a case of using the complexing agents described in DE-A-199 03 570 in sufficient amounts to complex the hyperforin. Explicit reference is made to both these references in connection with stabilising hyperforin.
EXAMPLE 1
Preparation of an Extract According to the Invention
3.1 kg of hypericum drug was homogenised for 1 min. with 6.5 times the quantity by weight of acetone 95%—EtOH 92% in the ratio of 8:2 as an extraction agent with ultraturrax (shielded from light). The solution was then extracted in the laboratory extractions vessel for 1 hour at 50° C. (N2 atmosphere/shielded from light). 5 g ascorbic acid was added to the extract solution (1% to the expected quantity of extract). The solution was drawn through a vacuum filter (Seitz Supra 1500). The drug residue was again twice extracted and filtered with the 6-fold quantity by weight under the same conditions.
5 g ascorbic acid was once again added to the combined filtrates. The solution was gently concentrated until dry (heat-band max. 50° C./shielded from light).
Yield: 490.02 g=15.8% (hyperforin content: 5.75%/hypericin content 0.45%).
Next, the sample was dissolved in 92% by weight ethanol and filtered through a G2 frit. A negligible residue (approx. 2–3 g) was left on the frit. 485 g of extract was then passed to a closed chromatography column, packed with Diaion HP-20.
Chromatography Conditions:
Sample 485 g, diluted with 92% by weight EtOH to 15 l
Column size Filling height 42 cm; radius 10 cm
Column filling Diaion HP-20, 0.3–0.8 mm grain size
Eluant 1. EtOH 92% by weight (100 l; → fraction 1)
2. EtOH 92% by weight (40 l; → fraction 2)
3. Acetone 100% (45 l; chlorophyll fraction)
Flow Separation approx. 1 1/min.
Yield:
Fraction 1 contained the main portion of the extract (412 g=85%; hyperforin content 6.3%; hypericin content 0.50%, total flavones 6.4%). This fraction was used in the invention examples as the St. John's wort extract according to the invention.
The extract showed no change of color at room temperature or at 30° C. over a period of 6 months.
EXAMPLE 2a
Hypericum Extract/Polyacrylate Gel
Component Quantity portion (%)
St. John's wort extract according to the 2.5
invention, in accordance with Example 1
Polyacrylic acid 1.5
Propylene glycol 2.5
Tromethamine solution (40%, in water) 5.5
Ethanol 96% by weight 40.0
Purified water 48.0
Preparation:
The gel former (polyacrylic acid 1–3%, preferably 1.5%) was dispersed in a mixture of water, ethanol and propylene glycol. The extract (0.5–5%, preferably 2.5%) was added and blended in. The tromethamine solution was added and blended in small increments. A homogenous gel is formed. Stabilisers such as ascorbic acid can then be added to this basic recipe.
The preparation showed no change of color at room temperature or at 30° C. over a 6-month period.
EXAMPLE 2b
Hypericum Extract—Tenside Gel
Component Quantity portion (%)
St. John's wort extract according to the 5.0
invention, in accordance with Example 1
Macrogol-glycerol hydroxy-stearate 35.0
Isopropyl-myristate 10.0
Neutral oil 10.0
Propylene glycol 5.0
Purified water 35.0
Preparation:
The St. John's wort extract, tenside (macrogol-glycerol-hydroxy-stearate), isopropyl-myristate, neutral oil and propylene glycol were blended until homogenous. Next, water was added while stirring. A homogenous gel is formed. Stabilisers such as ascorbic acid can be added to this basic recipe.
The preparation showed no change of color at room temperature or at 30° C. over a 6-month period.
EXAMPLE 2c
Hypericum Extract—Hydrocarbon Gel
Component Quantity portion (%)
St. John's wort extract according to the 5.0
invention, in accordance with Example 1
Vaseline 90.0
Propylene glycol 5.0
Preparation:
The vaseline was melted by heating; propylene glycol was added and blended in. The St. John's wort extract was then added, blended in and stirred while cold. A homogenous gel is formed.
The preparation showed no change of color at room temperature or at 30° C. over a 6-month period.
EXAMPLE 3
Anti-Viral Effect
The Herpes simplex 1 strain of virus (HSV-1), (source: McIntyre, ATCC) was used to test the anti-viral properties of the extract in this invention.
Various concentrations of the test substances were blended with 980 μl of virus solution at a quantity of 20 μl to assess the cyto-toxic concentration (TC50) and placed on a micro-titre dish with 3-day-old ape kidney cells (verocells) following a one-hour incubation period. After incubation of the dishes at 37° C. in an incubator for 5 days, a visual readout of the cell culture was performed, following HSV-1-specific cyto-pathogenic changes (CPE).
To determine “virostatic” action (inhibition test), the extract according to the invention or hypericin was added to a closed cohort of verocells in micro-titre dishes at various concentrations. After incubating for one hour, HSV-1 was then added at a concentration of 3000 TCID50/ml. The dishes were then incubated at 37° C. and 5% CO2 in the incubator. Assessment was carried out after 48–72 hours, using monoclonal antibodies and a specific colouring method.
Various concentrations of the extract according to the invention and hypericin were incubated in the incubator for 7 days to assess the cyto-toxic effect of verocells. Determining of cyto-toxicity was performed using an MTT test following a published procedure (Cinatl J. jr; Cinatl, J; Rabenau, H, Gümel, H; Doerr, H. W; (1993); “In-vitro anti-human immuno-deficiency virus activity of 2′, 3 dideoxynucleotides and their effect on clonal growth of hæmopoietic cells from human bone-marrow”, Arzneimittel-Frsch./Drug Res. 43, 622–625).
Assessment of the cyto-toxic concentration (TC50) and the virus-inhibiting concentration (IC50) was performed using linear regression. To calculate the therapeutic index, the formula TC50/IC50 was applied.
Results of the Investigations in the “Deactivation Test”
Concentrations applied in μg/ml
Preparation 100 50 10 1 0.5
St. John's wort n.d. n.d. 3.6 × 103 8.4 × 104 8.4 × 106
extract according
to the invention,
in accordance
with
Example 1
Hypericin 4.7 × 103 n.d. 4.7 × 106 n.d. n.d
The virus quantities applied were 1.5×107 TCID50. “Virus deactivation” was calculated from the difference between the initial virus quantities and the virus titres given above. N.d. means “not determined”, due to cyto-toxicity or the “virus-deactivating” effect found in preliminary trials.
Results of the Investigations in the “Inhibition Test”
Preparation TC50 (μg/ml) IC50 (μg/ml) Therapeutic index
St. John's wort extract 1.3 0.012 108
according to the
invention, in accordance
with Example 1
Hypericin 74.3 2.2 34
As can be seen from the investigations, hypericin showed a clear virus-deactivating action, as expected. It amounted to approx. 4 log10 stages at 100 μg/ml. Surprisingly, however, the extract according to the invention produced a significantly more potent effect in that it showed an equally strong inhibiting effect even at a concentration of just 10 μg/ml, comparable to the more intrinsically anti-viral St. John's wort extract ingredient hypericin, which is contained in the extract according to the invention at a portion of 0.5% only.
The potent anti-viral effect of the extract according to the invention was confirmed in the inhibition test.
EXAMPLE 4
Antibacterial Effect
Anti-microbial effects against various gram-positive bacteria were determined using the micro-dilution method. In the table below, we show the minimum inhibition concentration (MIC) and the minimum bactericide concentration (MBC) in each case.
MIC of extract
Hyperforin MIC according to the
Bacteria/fungi (μg/ml) invention (μg/ml)
Staphylococcus aureus (SA) 62.5 39.0
Staphylococcus saprophyticus 62.5–125  19.5
Methicillin-resistant SA 31.25 9.8–19.5
Enterococcus fæcalis 125 39.0
Enterococcus fæcium 125–250 19.5
Enterococcus durans 125 9.8–19.5
Listeria monocytogenes  15.6–31.25 2.5
Streptococcus pyogenes 15.6 2.5–4.9 
The extract according to the invention showed significantly more potent antibacterial effects on the gram-positive bacteria tested than would have been expected on the basis of its content of hyperforin, which is thought to be an ingredient with intrinsically antibacterial effects.
EXAMPLE 5
Anti-phlogistic Effect
The anti-phlogistic effects of hypericum extract according to the invention, also those of isolated ingredients, were tested in the Oleum Crotonis-ear-oedema model on male NRMI mice. After inducing a narcosis by the intra-peritonal injection of 60 mg/kg sodium-pento-barbital, the test substances were applied to the right ear in 10 μl acetone, whereas the left ear was treated with 10 μl acetone alone, as a control. 30 mins later, a local inflammation was triggered at the left ear by applying 50 μg Oleum Crotonis in 10 μl acetone. After 6 hours, the animals were sacrificed and inhibition of the inflammation reaction was quantified by weighing a sample of tissue drawn from both ears, using the following formula: [1−(GT/GL]×100; in the case of GT or GL, this deals with the difference in weight between the right and left ears of animals that have been treated with the test substance (GT), or only with the solvent (GL).
Inhibition of neutrophile granulocyte accumulations in inflamed tissue was obtained by determining myelo-peroxidase (MPO) in the ear homogenates. To this end, biopsy samples were recorded in 1 ml hexadecyl-trimethyl ammonium bromide (HTAB) buffers, homogenised with a glass homogeniser at 4° C. and then given ultrasound treatment for 10 seconds in a sonicator. After centrifuging at 4° C. with 3000 g for 10 mins, the supernatant was removed and retained for analysing at −70° C. Determining the MPO was performed in micro-titre dishes after adding H2O2 and the O-dianisidine-dihydrochloride indicator as a kinetic measure, over a period of 5 mins at 450 nm. Assessment was carried out against a standard curve with horseradish peroxidase, and was obtained as an mU enzyme activity per mg of tissue.
The results of the investigations after applying 250 μg of the test substance or 1000 μg of the extract according to the invention to the left ear in each case are summarised in the following table.
Ingredient Oedema inhibition (%) MPO inhibition (%)
Extract according to the 69 72
invention
Amento-flavone 82 70
Biapigenine 83 86
Catechol 36 41
Chlorogenic acid 14 16
Epicatechol 1 45
Hyperforin 65 62
Hypericin 6 48
Hyperoside −27 39
Isoquercitrin −29 73
Camphor oil 91 96
Luteolin 70 91
Myricetin 17 75
Quercetin 82 97
Quercitrin −26 23
Rutin 38 55
The extract according to the invention was applied in the investigation described above in quantities of 1000 μg. As is evident from Example 1, the extract according to the invention used in accordance with Example 1 (fraction 1) contains 6.3% hyperforin as the active ingredient, with quantitatively the largest portion in the extract. 1000 μg extract thus corresponds to 63 μg hyperforin. The comparison substances were again administered in quantities of 250 μg. This means the test substances were administered at about four times the amount compared with hyperforin. In spite of this, the extract according to the invention shows markedly greater inhibition compared with hyperforin, used as a test substance. Here we see once again the synergistic effect between hyperforin and other ingredients of the extract according to the invention that are relevant for its effectiveness. It thus emerges clearly that the sum-total of the individual compounds is important for its beneficial pharmaceutical properties, where particular flavonoids (e.g. amentoflavone, biapigenine, camphor oil, luteolin, quercetin) are quite plainly of special significance.
EXAMPLE 6
Proliferation of Human Keratinocytes (HaCaT Cells)
The effects of the extracts according to the invention and various ingredients on the proliferation of human keratinocytes were obtained by using the HaCaT cell-line. The cells (10,000–15,000) were disseminated in 200 μl DMEM with 5% foetal calf serum in 96-well F-form micro-titre dishes and incubated at 37° C. at absence of test substances in an incubator. Cell proliferation was determined by measuring the incorporation of 3H methyl-thymidine (0.5 μCi/well) over the last 6 hours in the culture.
Ingredient Concentration (μg/ml) Inhibition (%)
Extract according 30 81
to the invention
Amento-flavone 10 68
Biapigenine 10 15
Catechol 10 14
Chlorogenic acid 10 −9
Epicatechol 10 13
Hyperforin Na 10 97
Hypericin 10 100
Hyperoside 10 −8
Isoquercitrin 10 83
Camphor oil 10 44
Luteolin 10 92
Myricetin 10 26
Quercetin 10 −29
Quercitrin 10 35
Rutine 10 9
As is clear from the results set out above, the anti-proliferative properties of the extract according to the invention quite plainly have 5 their basis in the combined effect of hypericin and hyperforin, together with certain flavone compounds, for example isoquercitrin and luteolin.
EXAMPLE 7
Inhibition of 5α Reductase
Investigations of 5a reductase inhibition were carried out on cells of the human prostate-cancer cell-line DU145. The cells (250,000) were disseminated in 5 ml of RPMI 1640 medium with 10% foetal calf serum (FCS) in 6-well cell-culture dishes and incubated at 37° C. in an incubator. After four days, the medium against RPMI 1640 was replaced, with the addition of 10% charcoal-stripped FCS. On the following day, the test substances and 14C testosterone were applied and another 18 hours later, supernatant of the cells were removed. The supernatant of the cells were mixed with 2.5 ml ethyl acetate and then centrifuged for 10 mins with 500 g at room temperature. The organic phase was removed and transferred over to a small glass tube. Extraction was then repeated by again applying 2.5 ml ethyl acetate. The combined organic phases were evaporated down at 37° C. under N2 fumigation until dry; the residue was taken into 50 μl ethyl acetate and then separated out twice on a silica-gel 60 TLC dish, with ethyl acetate/cyclohexane (1:1) as mobile phase. The testosterone metabolites so formed were localised with the aid of a linear analyser, and inhibition of 5α reductase was obtained at the dihydro-testosterone peak by comparison with the solvent control.
Concentration Inhibition of 5α
Ingredient (μg/ml) reductase (%)
Extract according to the 500 44
invention in accordance
with Example 1
Amento flavone 30 −15
Biapigenine 30 −4
Catechol 30 −15
Chlorogenic acid 30 3
Epicatechol 30 −6
Hyperforin Na 5 10
Hypericin 30 −24
Hyperoside 30 −1
Isoquercitrin 30 −5
Camphor oil 30 12
Luteolin 30 42
Myricetin 30 29
Quercetin 30 46
Quercitrin 30 −29
Rutin 30 −6
The extract according to the invention shows a marked inhibiting effect on 5a reductase. The concentration of test substances used, at 30 μg/ml, corresponds to the concentration of hyperforin, which is quantitatively the most important ingredient in the extract according to the invention in accordance with Example 1, fraction 1.
In contrast to the extract according to the invention (500 μg/ml), hyperforin turned out to be cyto-toxic at the concentration of some 30 μg/ml corresponding to its proportion of the total extract: hence it was tested only at a concentration of 5 μg/ml. It can be seen from the results that, even at the high concentrations of individual ingredients tested, which clearly exceed their respective proportions in the extract according to the invention, none of these compounds produced an effect exceeding that of the total extract. The overall effect of the extract according to the invention can therefore be explained only by the combined effect of all the ingredients included.
EXAMPLE 8
Stability of the Active Ingredients, in Particular Hyperforin, in the Preparations According to the Invention)
Hyperforin, which is known to be chemically unstable, is included complete in a gel according to the invention in accordance with Example 2a, as can be shown by the quantitative determination of the hyperforin it contains; in other words, no decomposition occurs in producing the gel.
Measured hyperforin
Preparation concentration (%) Recovery (%)
St. John's wort extract 6.33 —
according to the invention
in accordance with Example 1
St. John's wort extract 0.15 99.0
according to the invention
in accordance with
Example 1/polyacrylate gel

Claims (24)

The invention claimed is:
1. An extract of Hypericum perforatum L. having a hyperforin content of 2–8% by weight, a total hypericin content of 0.2–1% by weight and a total flavones content of 2–8% by weight and where the extract is substantially free of chlorophyll and proanthocyanidins.
2. The extract according to claim 1 having a hyperforin content of 4–8% by weight, a total hypericin content of at least 0.4–1% by weight and a total flavone content of 4–8% by weight.
3. The extract according to claim 1 characterised in that the extract in addition contains a stabiliser in an amount of 0.01 to 5% by weight.
4. The extract according to claim 3, characterised in that the stabiliser is selected from the group consisting of ascorbic acid, ascorbic acid esters, organic thiol compounds and complexing agents or mixtures thereof.
5. The extract according to claim 4, wherein the stabilizer is selected from organic thiol compounds and is cysteine or glutathione and the complexing agent is selected from the group consisting of cyclic oligo-saccharides, silicic acids, citric acid, sugar alcohols, cellulose derivatives, polyvinyl-pyrrolidones and vinyl-pyrrolidone-vinylacetate-copolymers, or mixtures thereof.
6. A method for the preparation of an extract of Hypericum perforatum L., comprising extracting dried Hypericum perforatum L. plant material with acetone, aqueous acetone, ethanol, aqueous ethanol, or a solvent mixture containing acetone and ethanol to yield a crude extraction mixture, and removing from the crude extraction mixture chlorophyll and proanthocyanidins by filtration using an adsorbing agent.
7. A method according to claim 6, wherein the extracting is done with aqueous acetone or aqueous ethanol, or a mixture of both solvents.
8. A method according to claim 7, wherein ≧90% by weight aqueous acetone or ≧90% by weight aqueous ethanol, or a mixture of both solvents, is deployed for the extracting.
9. A method according to claim 7, wherein the acetone and ethanol solvent mixture has a ratio of 8:2.
10. A method according to any one of claim 6, wherein the adsorbing agent is selected from the group consisting of resins based on polystyrol and argillaceous earth.
11. A method according to claim 6, further comprising adding a stabiliser to the extract.
12. A method according to claim 11, wherein the stabiliser is selected from the group consisting of ascorbic acid, ascorbic acid esters, organic thiol compounds, and complexing agents or mixtures thereof.
13. A method according to claim 12, wherein the stabilizer is selected from organic thiol compounds and is cysteine or glutathione, and the complexing agent is selected from the group consisting of cyclic oligo-saccharides, silicic acids, citric acid, sugar alcohols, cellulose derivatives, polyvinyl-pyrrolidones and vinyl-pyrrolidone-vinylacetate-copolymers, or mixtures thereof.
14. A method according to claim 6, wherein aqueous acetone, aqueous ethanol, or a mixture of both solvents, is used for the extracting; the adsorbing agent is selected from the group consisting of resins based on polystyrol and argillaceous earth; further comprising adding and a stabiliser selected from the group consisting of ascorbic acid, ascorbic-acid esters, organic thiol compounds, and complexing agents or mixtures thereof to the extract.
15. A method according to claim 14, wherein the stabilizer is selected from organic thiol compounds and is cysteine or glutathione, and the complexing agent is selected from the group consisting of cyclic oligo-saccharides, silicic acids, citric acid, sugar alcohols, cellulose derivatives, polyvinyl-pyrrolidones and vinyl-pyrrolidone-vinylacetate-copolymers, or mixtures thereof.
16. A pharmaceutical composition comprising the extract according to claim 1 together with at least one conventional pharmaceutically acceptable excipient for topical application.
17. A pharmaceutical composition according to claim 16 which is formulated as a gel.
18. A method for preparing a pharmaceutical composition according to claim 16, comprising mixing the extract and the at least one conventional pharmaceutically acceptable excipient with a hyperforin stabiliser.
19. A method according to claim 18, wherein the stabiliser is selected from the group consisting of ascorbic acid, ascorbic acid esters, organic thiol compounds and complexing agents or mixtures thereof.
20. A method according to claim 19, wherein the stabilizer is selected from organic thiol compounds and is cysteine or glutathione, and the complexing agent is selected from the group consisting of cyclic oligo-saccharides, silicic acids, citric acid, sugar alcohols, cellulose derivatives, polyvinyl-pyrrolidones and vinyl-pyrrolidone-vinylacetate-copolymers, or mixtures thereof.
21. A method for the treatment of skin and mucous membrane irritations and disorders comprising administering to a patient in need of such treatment a therapeutically effective amount of a the extract according to claim 1.
22. A method according to claim 21, wherein the skin and mucous membrane irritations and disorders are selected from the group consisting of acne, atopic dermatitis, neuro-dermatitis, psoriasis, stomatitis, herpes zoster, herpes labialis (lip herpes), warts, varicella (chickenpox), sores, burns, and bacterial or viral skin and mucous membrane infections that are accompanied by cell proliferation and inflammation.
23. An extract according to claim 1, having a hyperforin content of 4–8% by weight, a total hypericin content of at least 0.4%–1% by weight and a total flavone content of 4–8% by weight, and comprising a stabiliser in an amount of 0.01 to 5% by weight, wherein the stabiliser is selected from the group consisting of ascorbic acid, ascorbic-acid esters, organic thiol compounds and complexing agents or mixtures thereof.
24. An extract according to claim 23, wherein the stabilizer is selected from organic thiol compounds and is cysteine, and the complexing agent is selected from the group consisting of cyclic oligo-saccharides, silicic acids, citric acid, sugar alcohols, cellulose derivatives, polyvinyl-pyrrolidone and vinyl-pyrrolidone-vinylacetate-copolymers, or mixtures thereof.
US10/451,714 2000-12-22 2001-12-21 Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament Expired - Fee Related US7166310B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE10064284 2000-12-22
DE10064284 2000-12-22
DE10064284.5 2000-12-22
DE10131641.0 2001-06-29
DE10131641A DE10131641A1 (en) 2000-12-22 2001-06-29 St. John's wort extracts having reduced chlorophyll and proanthocyanidin contents, useful as topical medicaments, e.g. for treating stomatitis, acne, viral infections or psoriasis
DE10131641 2001-06-29
PCT/EP2001/015281 WO2002051427A1 (en) 2000-12-22 2001-12-21 Improved and stable extract from hypericum perforatum l., method for the production thereof and its use as a topical medicament

Publications (2)

Publication Number Publication Date
US20040137088A1 US20040137088A1 (en) 2004-07-15
US7166310B2 true US7166310B2 (en) 2007-01-23

Family

ID=7668450

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/451,714 Expired - Fee Related US7166310B2 (en) 2000-12-22 2001-12-21 Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament

Country Status (10)

Country Link
US (1) US7166310B2 (en)
EP (1) EP1345614B1 (en)
JP (1) JP4177666B2 (en)
CN (1) CN1264526C (en)
AT (1) ATE273017T1 (en)
DE (2) DE10131641A1 (en)
DK (1) DK1345614T3 (en)
ES (1) ES2227318T3 (en)
MX (1) MXPA03005657A (en)
WO (1) WO2002051427A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071839A1 (en) * 2003-11-24 2007-03-29 Indena S.P.A. Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne
KR101121883B1 (en) * 2010-11-24 2012-03-20 주식회사 바이오에프디엔씨 A skin external composition containing callus extract drived from saint john's wart
RU2541134C2 (en) * 2012-12-06 2015-02-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Дагестанский Государственный Технический Университет" (Дгту) Method for preparing dry herbal extract of st. john's wort
EP3135341A1 (en) 2015-08-27 2017-03-01 Latvijas Universitate Cosmetic skin whitening compositions containing extracts derived from in vitro propagated hypericum hirsutum

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020756A1 (en) * 2002-04-09 2003-10-09 Sinclair Pharma S R L TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DERMATITIS
FR2848455B1 (en) * 2002-12-13 2006-03-03 Oreal USE OF A PLANT EXTRACT OF THE CLUSIACEAE FAMILY IN THE PREPARATION OF A COMPOSITION FOR CORRECTING OR PREVENTING DISORDERS ASSOCIATED WITH A FAT SKIN
WO2004054598A1 (en) * 2002-12-13 2004-07-01 L'oreal Use of plant extract of the family of clusiaceae for preparing a composition for treating or preventing greasy skin-mediated disorders
US7357950B2 (en) 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US7666451B2 (en) 2003-03-21 2010-02-23 Elizabeth Anne Mazzio Method of treating dyshidrosis(pompholyx) and related dry skin disorders
BG65694B1 (en) * 2003-12-31 2009-07-31 НАЙДЕНОВ Владимир MEANS FOR TREATMENT OF DERMATOSES
EP1591125A1 (en) * 2004-04-19 2005-11-02 Universitätsklinikum Freiburg Pharmaceutical composition comprising extracts of lichens and hypericum
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
DE102005004438B4 (en) * 2005-01-31 2007-12-20 Raps Gmbh & Co. Kg Rooibos extract with increased aspalathin content, process for producing such rooibos extract and cosmetic agent containing such Rooibos extract
WO2006135965A1 (en) * 2005-06-20 2006-12-28 Dynamiclear Pty Ltd Composition for treating skin lesions
AU2009217410B2 (en) * 2005-06-20 2011-07-28 Sci-Chem International Pty. Ltd. Composition for treating skin lesions
US20110064826A1 (en) * 2005-06-20 2011-03-17 John Spurge Composition for treating skin lesions
DE102006058450A1 (en) * 2006-12-12 2008-06-19 Eberhard-Karls-Universität Tübingen Preparations for the inhibition of prostaglandin E2 synthesis
US8828941B2 (en) * 2007-02-23 2014-09-09 Divya Diwan Composition and method for the treatment or prevention of spinal disorders
ES2343349B1 (en) * 2009-01-27 2011-07-21 Manuel Herrero Cervera CREAM FOR THE TREATMENT OF HERPES ZOSTER.
WO2011069184A1 (en) * 2009-12-08 2011-06-16 Dynamiclear Pty Ltd Composition for treating skin lesions
IT1400386B1 (en) * 2010-05-27 2013-05-31 Roberto Logi KIT OF PARTS FOR THE TREATMENT AND / OR PREVENTION OF SKIN ULCERS
CN103091439A (en) * 2013-01-07 2013-05-08 天津科技大学 Method for establishing HPLC fingerprints of hypericum ascyron medicinal materials and standard fingerprints and application thereof
WO2022058332A1 (en) * 2020-09-16 2022-03-24 Dermo Magister, S.L. Viricidal composition and uses thereof
CN116333362B (en) * 2023-02-10 2024-03-29 西北农林科技大学 Preparation method and application of hypericin/purple phosphorus quantum dots/bacterial cellulose composite membrane

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256452A2 (en) 1986-08-08 1988-02-24 Yeda Research And Development Company Limited Antiviral pharmaceutical compositions containing hypericin or pseudohypericin
EP0599307A1 (en) 1992-11-27 1994-06-01 Dr. Willmar Schwabe GmbH & Co. St.-John's-wort dry extract, process for its preparation and its use
DE19619512C1 (en) 1995-09-29 1997-07-31 Schwabe Willmar Gmbh & Co Stable dry extract of Hypericum perforatum L., Saint John's wort - with stabiliser and higher hyperforin content, used to treat depression and psycho-vegetative illness, obtained by solvent extraction etc.
DE19903570A1 (en) 1998-11-04 2000-05-11 Schwabe Willmar Gmbh & Co Stable preparations with hyperforin
US6063401A (en) * 1998-05-06 2000-05-16 M.E. Cody Products, Inc. Plantago major and hypericum perforatum compound for use in treating a tobacco or nicotine habit
WO2000030660A2 (en) 1998-11-25 2000-06-02 Universitätsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
DE19854446A1 (en) 1998-11-25 2000-06-08 Univ Ludwigs Albert Use of hyperforin for treating cancer, or in topical compositions optionally together with hypericin for treating e.g. inflammatory skin disease, skin aging or bacterial skin infections
US6113907A (en) * 1997-04-15 2000-09-05 University Of Southern California Pharmaceutical grade St. John's Wort
US6241988B1 (en) * 1997-04-08 2001-06-05 Dr. Willmar Schwabe Gmbh & Co. Stable extract of hypericum perforatum L., a method for producing the same, and corresponding pharmaceutical preparations
US6245362B1 (en) * 1995-12-18 2001-06-12 Dreluso Pharmazeutika Dr. Elten & Sohn Gmbh Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medication
US6280736B1 (en) 1995-09-29 2001-08-28 Ur. Willmar Schwabe Gmbh & Co, Stable extract of Hypericum perforatum L.,process for preparing the same and pharmaceutical compositions
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
US6322824B1 (en) 1998-02-13 2001-11-27 Willmar Schwabe Gmbh & Co. Use of hyperforin and hyperforin-containing extracts in the treatment of dementia diseases

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256452A2 (en) 1986-08-08 1988-02-24 Yeda Research And Development Company Limited Antiviral pharmaceutical compositions containing hypericin or pseudohypericin
EP0599307A1 (en) 1992-11-27 1994-06-01 Dr. Willmar Schwabe GmbH & Co. St.-John's-wort dry extract, process for its preparation and its use
DE19619512C1 (en) 1995-09-29 1997-07-31 Schwabe Willmar Gmbh & Co Stable dry extract of Hypericum perforatum L., Saint John's wort - with stabiliser and higher hyperforin content, used to treat depression and psycho-vegetative illness, obtained by solvent extraction etc.
US6280736B1 (en) 1995-09-29 2001-08-28 Ur. Willmar Schwabe Gmbh & Co, Stable extract of Hypericum perforatum L.,process for preparing the same and pharmaceutical compositions
US6245362B1 (en) * 1995-12-18 2001-06-12 Dreluso Pharmazeutika Dr. Elten & Sohn Gmbh Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medication
US6241988B1 (en) * 1997-04-08 2001-06-05 Dr. Willmar Schwabe Gmbh & Co. Stable extract of hypericum perforatum L., a method for producing the same, and corresponding pharmaceutical preparations
US6113907A (en) * 1997-04-15 2000-09-05 University Of Southern California Pharmaceutical grade St. John's Wort
US6322824B1 (en) 1998-02-13 2001-11-27 Willmar Schwabe Gmbh & Co. Use of hyperforin and hyperforin-containing extracts in the treatment of dementia diseases
US6063401A (en) * 1998-05-06 2000-05-16 M.E. Cody Products, Inc. Plantago major and hypericum perforatum compound for use in treating a tobacco or nicotine habit
DE19903570A1 (en) 1998-11-04 2000-05-11 Schwabe Willmar Gmbh & Co Stable preparations with hyperforin
DE19854446A1 (en) 1998-11-25 2000-06-08 Univ Ludwigs Albert Use of hyperforin for treating cancer, or in topical compositions optionally together with hypericin for treating e.g. inflammatory skin disease, skin aging or bacterial skin infections
WO2000030660A2 (en) 1998-11-25 2000-06-02 Universitätsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Erdelmeier, Studies in Natural Products Chemistry, (2000) 22:643-716.
Harald C. J. Orth and Peter C. Schmidt, "Stability and Stabilization of Hyperforin" Drugs made in Germany 42: pp. 110-113 (1999).
Lavie, et al., Medicinal Research Reviewsi, (1995) 15(2):11-119.
Lavie, et al., Proc. Natl. Acad. Sci, USA, (1989) 86:5963-5967.
Maisenbacher, Tobingen University Dissertation, (1991) pp. 6-15.
Muller, et al., Deutsche Apotheker Zeitung, (1999) 139(17):49-58.
Schempp, et al., The Lancet, (1999) 353:2129.

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071839A1 (en) * 2003-11-24 2007-03-29 Indena S.P.A. Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne
US7597915B2 (en) * 2003-11-24 2009-10-06 Indena S.P.A. Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne
AU2004294691B2 (en) * 2003-11-24 2010-07-08 Indena S.P.A. Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne
KR101121883B1 (en) * 2010-11-24 2012-03-20 주식회사 바이오에프디엔씨 A skin external composition containing callus extract drived from saint john's wart
RU2541134C2 (en) * 2012-12-06 2015-02-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Дагестанский Государственный Технический Университет" (Дгту) Method for preparing dry herbal extract of st. john's wort
EP3135341A1 (en) 2015-08-27 2017-03-01 Latvijas Universitate Cosmetic skin whitening compositions containing extracts derived from in vitro propagated hypericum hirsutum

Also Published As

Publication number Publication date
MXPA03005657A (en) 2004-12-03
WO2002051427A1 (en) 2002-07-04
CN1264526C (en) 2006-07-19
JP4177666B2 (en) 2008-11-05
DK1345614T3 (en) 2004-11-29
US20040137088A1 (en) 2004-07-15
ES2227318T3 (en) 2005-04-01
WO2002051427A8 (en) 2003-02-20
EP1345614A1 (en) 2003-09-24
EP1345614B1 (en) 2004-08-11
DE10131641A1 (en) 2002-06-27
CN1481250A (en) 2004-03-10
DE50103262D1 (en) 2004-09-16
ATE273017T1 (en) 2004-08-15
JP2004517101A (en) 2004-06-10

Similar Documents

Publication Publication Date Title
US7166310B2 (en) Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament
US7955626B2 (en) Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester
US20100298423A1 (en) Nutraceutical composition from garcinia mangostana
EP2633885A1 (en) Compounds and mixtures for affecting inflammatory conditions
US6979471B1 (en) Composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from Glycyrrhiza glabra
US4254112A (en) Inula extract, its method of preparation and its use as pharmaceutical
Li et al. Astragalin attenuates UVB radiation-induced actinic keratosis formation
KR102139328B1 (en) Cosmetic composition for skin cooling or improving skin redness with the extract of Eucommia Ulmoides bark
KR102400090B1 (en) Cosmetic Composition for Reducing Skin Wrinkle
US10383841B2 (en) Antimicrobial and antiinflammatory composition
CN111056935B (en) Dearomatized isopentenyl acyl phloroglucinol derivative, pharmaceutical composition and application thereof
KR20190133562A (en) Antimicrobial and Antifungal Composition Containing Clove, Hibiscus, and Coconut Extract Complex as Active Ingredient
WO2021119826A1 (en) Extracts enriched with polyphenolic compounds and related methods
Yan et al. Ginseng oligosaccharides protect neurons from glutamate-induced oxidative damage through the Nrf2/HO-1 signaling pathway
KR20180081327A (en) Composition for skin conditioning comprising Adenophora Stricta extract
US4465673A (en) Pentagalloylglucose antiviral composition
KR20180059318A (en) Cosmetic composition comprising an extract of a mixture comprising baked glycyrrhiza uralensis fisch, cyperus rotundus l. and curcuma longa l.
WO2021110185A1 (en) Phenolic dihydrobenzofurane derivatives, medical and cosmetic preparations containing these derivatives, and use thereof
EP2133323A1 (en) The production and use of 3,5-dicaffeoyl-4-malonylquinic acid
Geiger et al. Ellagitannins from Tormentillae rhizoma and Alchemillae herba
Bhandari et al. Antibacterial activity of Hydrastis canadensis extract on selected periodontal pathogens: an in vitro study
KR20140145268A (en) Cosmetic composition containing compound for pore convergence and acne suppression.
EP4137143A1 (en) Composition for anti-oxidation and anti-inflammation comprising salvia plebeia r br extract and centella asiatica extract
JPH05105613A (en) Beautifying cosmetic composition
Itankar et al. In–Vitro Anti-Cancer study of biotransformed material (extract) of calendula officinalis by MTT assay

Legal Events

Date Code Title Description
AS Assignment

Owner name: WILLMAR SCHWABE GMBH & CO., GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOCH, EGON;ERDELMEIER, CLEMENS;HERRMANN, JOACHIM;REEL/FRAME:014993/0248;SIGNING DATES FROM 20040107 TO 20040114

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20190123